Power 3 Medical (PWRM) Researching Early Detection of Cancer and Neurodegenerative Diseases.avi
Today’s company highlight is Power 3 Medical Products Incorporated trading with the symbol PWRM Power 3 Medical’s management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few. Approximately 5.3 million Americans have Alzheimer’s disease (AD). Unless a cure or prevention is found, that number will increase to between 11 and 16 million by 2050. As many as one million Americans live with Parkinson’s disease, which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and Lou Gehrig’s disease. About 1 in 8 women in the United States (12%) will develop invasive breast cancer over the course of her lifetime. An estimated 5000 people in the United States are diagnosed with Amyotrophic (A MY O TRO FIC) lateral sclerosis, often referred to as “Lou Gehrig’s Disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms. Power 3 Medical, a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, applies proprietary methodologies to discover and identify protein biomarkers associated …



